TAK-994对药物诱导的肝损伤的机制性调查
Tadahiro Shinozawa1, Kazumasa Miyamoto1, Kevin S Baker2
1Takeda Pharmaceutical Company Ltd, Fujisawa, Kanagawa 251-8555, Japan.
概括
研究了TAK-994的药物诱导性肝损伤 (DILI),TAK-994是一种素激动剂. 在代谢后的共价结合被确定为特异性DILI的可能原因,这表明剂量降低可能会减轻风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝毒性 肝毒性 肝毒性
- 药物开发 药物开发
背景情况:
- 药物诱导性肝损伤 (DILI) 在药物开发中构成了重大挑战.
- 一种素受体2激动剂TAK-994因严重的DILI而从II期试验中撤回.
- 临床前模型和物种差异使DILI预测变得复杂.
研究的目的:
- 为了研究TAK-994引起的DILI的机制.
- 评估TAK-994在肝细胞培养系统中的潜在负担.
- 为了将临床前发现与DILI的临床观察相关联.
主要方法:
- 在肝细胞培养物中评估了TAK-994的细胞毒性,线粒体毒性和药物载体相互作用.
- 在代谢激活后评估共价结合潜力.
- 将体外发现与来自老鼠,非人类灵长类动物和小鼠研究的体内数据进行比较.
主要成果:
- 在老鼠和非人类灵长类动物的研究中没有观察到肝损伤.
- 针对小鼠的研究显示,在细胞染色体P450诱导后的临床相关剂量下,单细胞亡.
- 肝细胞培养揭示了已知的内在DILI机制的广泛安全边际.
- 在TAK-994代谢后,发现了潜在的共价结合负债.
结论:
- 在人类中,TAK-994诱导的DILI很可能是特异性的,在肝脏代谢后由共价结合驱动.
- 标准的临床前模型无法预测这种特定的DILI机制.
- 减少每日总剂量和共价结合潜力可能会降低特异性DILI的发生率.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
26
Drug Metabolism: Phase I Reactions
3.0K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.0K
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
138
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
138
Methods for Studying Drug Absorption: In situ
201
In situ experiments, such as the Doluisio method and Single-Pass Perfusion technique, provide critical insights into drug uptake by simulating in vivo conditions for drug absorption.
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
201


